Tech Company Financing Transactions
Calistoga Pharmaceuticals Funding Round
Calistoga Pharmaceuticals, based in Seattle, raised $40 million from Alta Partners, Amgen Ventures and Frazier Healthcare Partners.
Transaction Overview
Company Name
Announced On
6/30/2010
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors
Alta Partners (Ed Hurwitz)
Frazier Healthcare Partners (James Topper)
Three Arch Partners (Richard Lin)
Proceeds Purpose
The funds will be used to advance Calistoga Pharmaceuticals' drug development pipeline of isoform-selective PI3K inhibitors. CAL-101, an oral, delta selective PI3K inhibitor, is currently being evaluated as a single agent in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (iNHL), mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) and in combination with rituximab or bendamustine in patients with relapsed or refractory iNHL or CLL.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2101 - 4th Ave. 1960
Seattle, WA 98121
USA
Seattle, WA 98121
USA
Phone
Website
Email Address
Overview
Calistoga Pharmaceuticals, is developing a drug candidate acquired from Icos that has potential to treat various forms of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carol Gallagher
Chief Financial Officer
Andrew Guggenhime
Chief Medical Officer
Albert Yu
VP - R & D
Langdon Miller
Browse more venture capital transactions:
Prev: 6/30/2010: EpiEP venture capital transaction
Next: 6/30/2010: Arcxis Biotechnologies venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs